Interleukin 17A infusion has no acute or long-term hypertensive action in conscious unrestrained male mice

Sai Sindhu Thangaraj, Camilla Enggaard, Jane Stubbe, Yaseelan Palarasah, Pernille B.L. Hansen, Per Svenningsen, Boye L. Jensen*

*Corresponding author for this work

Research output: Contribution to journalJournal articleResearchpeer-review

Abstract

Interleukin 17A (IL-17A) is a candidate mediator of inflammation-driven hypertension, but its direct effect on blood pressure is obscure. The present study was designed to test the hypothesis that systemic IL-17A concentration-dependently increases blood pressure and amplifies ANGII-induced hypertension in mice. Blood pressure was measured by indwelling chronic femoral catheters before and during IL-17A infusion w/wo angiotensin II (ANGII, 60ng/kg/min) in male FVB/n mice. Baseline blood pressure was recorded, and three experimental series were conducted: (1) IL-17A infusion with increasing concentrations over 6 days (two series with IL-17A from two vendors, n = 11); (2) ANGII infusion with IL-17A or vehicle for 9 days (n = 11); and (3) acute bolus infusions with four different concentrations (n = 5). Plasma IL-17A and IL-6 concentrations were determined by ELISA. Mean arterial and systolic blood pressures (MAP, SBP) decreased significantly after IL-17A infusion while heart rate was unchanged. In these mice, plasma IL-17A and IL-6 concentrations increased up to 3500- and 2.4-fold, respectively, above baseline. ANGII infusion increased MAP (~ 25 mmHg) and co-infusion of IL-17A attenuated ANGII-induced hypertension by 4.0 mmHg. Here, plasma IL-17A increased 350-fold above baseline. Acute IL-17A bolus infusion did not change blood pressure or heart rate. IL-17A receptor and IL-6 mRNAs were detected in aorta, heart, and kidneys of mice after IL-17A infusion. Nonphysiologically high concentrations of IL-17A reduce baseline blood pressure and increase IL-6 formation in male FVB/n mice. It is concluded that IL-17A is less likely to drive hypertension as the sole cytokine mediator during inflammation in vivo.

Original languageEnglish
JournalPflugers Archiv European Journal of Physiology
Volume474
Issue number7
Pages (from-to)709-719
ISSN0031-6768
DOIs
Publication statusPublished - Jul 2022

Bibliographical note

Publisher Copyright:
© 2022, The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Keywords

  • Hypertension
  • IL-17A
  • Inflammation
  • Blood Pressure/physiology
  • Animals
  • Hypertension/chemically induced
  • Male
  • Interleukin-17/adverse effects
  • Mice
  • Angiotensin II/pharmacology
  • Interleukin-6

Fingerprint

Dive into the research topics of 'Interleukin 17A infusion has no acute or long-term hypertensive action in conscious unrestrained male mice'. Together they form a unique fingerprint.

Cite this